UniQure Shares Plunge 50% as FDA Rejects AMT‑130 BLA, Sparking Investor Investigation
UniQure’s share plunge after the FDA flagged AMT‑130 data highlights regulatory risk, legal investigations, and a bearish market—find out why investors are concerned.
2 minutes to read
